Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
